Jason Rhodes is a partner and focuses on creating and building novel therapeutics companies.
Jason is the chairman and was the founding CEO of Generation Bio (NASDAQ: GBIO) and Dyne Therapeutics (NASDAQ: DYN). He is also on the boards of Replimune (NASDAQ: REPL), Gemini Therapeutics (NASDAQ: GMTX), Accent Therapeutics, Be Biopharma, K36, Rectify Pharmaceuticals, and Third Harmonic Bio. He was the chairman and founding CEO of Disarm Therapeutics, acquired by Eli Lilly in 2020.
Previously, Jason held leadership positions at Epizyme (NASDAQ: EPZM), where he was President and built the company from early stage research into the clinic and through a successful IPO in 2013, and at Alnylam Pharmaceuticals (NASDAQ: ALNY), where he led business development. Jason was also a founder and partner with Fidelity Biosciences (now F-Prime Capital), the life sciences venture capital arm of Fidelity Investments, where he led investments in therapeutics companies including FoldRx, acquired by Pfizer.
Jason received his BA from Yale University and his MBA from the Wharton School of the University of Pennsylvania.
He is a member of the advisory board of the Harvard Institute for RNA Medicine, the Blavatnik Fund at Yale University, and the Berklee College of Music Presidential Advisory Council. Jason spends his free time mountain biking and loudly watching Spanish fútbol with his family.
What is Jason P. Rhodes' net worth?
The estimated net worth of Jason P. Rhodes is at least $17,079.34 as of November 14th, 2024. Ms. Rhodes owns 15,962 shares of Generation Bio stock worth more than $17,079 as of December 26th. This net worth evaluation does not reflect any other investments that Ms. Rhodes may own. Learn More about Jason P. Rhodes' net worth.
How do I contact Jason P. Rhodes?
Has Jason P. Rhodes been buying or selling shares of Generation Bio?
Jason P. Rhodes has not been actively trading shares of Generation Bio during the past quarter. Most recently, Jason P. Rhodes sold 16,586 shares of the business's stock in a transaction on Wednesday, September 29th. The shares were sold at an average price of $24.59, for a transaction totalling $407,849.74. Learn More on Jason P. Rhodes' trading history.
Who are Generation Bio's active insiders?
Are insiders buying or selling shares of Generation Bio?
In the last twelve months, insiders at the sold shares 2 times. They sold a total of 9,164 shares worth more than $22,370.96. The most recent insider tranaction occured on July, 1st when COO Antoinette Paone sold 6,719 shares worth more than $18,410.06. Insiders at Generation Bio own 21.1% of the company.
Learn More about insider trades at Generation Bio. Information on this page was last updated on 7/1/2024.
